Efficacy and Safety of Resveratrol Supplements on Blood Lipid and Blood Glucose Control in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
What this study found
Resveratrol supplementation may improve insulin resistance and glycemic control in adults with type 2 diabetes: HOMA-IR reduced by 0.99 (95% CI −1.61 to −0.38; P = 0.002); HbA1c reduced by 0.45 percentage points (95% CI −0.73 to −0.16; P = 0.002); fasting glucose reduced by 19.61 mg/dL (95% CI −26.02 to −13.20; P < 0.00001); fasting insulin reduced (SMD −0.67; 95% CI −1.21 to −0.14; P = 0.01). No significant changes in TC (−7.11; 95% CI −16.28 to 2.06; P = 0.13), TG (−2.15; 95% CI −5.52 to 1.22; P = 0.21), or LDL-C (−6.84; 95% CI −16.60 to 2.92; P = 0.17). Adverse events did not differ…
- Study & population
- Adults with type 2 diabetes mellitus; 15 randomized controlled trials comprising 896 participants; mixed genders; mean ages generally in the 50s–60s; multicountry settings (e.g., Iran, China, Japan, Hungary, Egypt, India, Singapore).
- Intervention
- Oral resveratrol supplements in capsule form; regimens varied by trial (examples include 100 mg/day, 240 mg BID, 400–500 mg/day, 240 mg BID, 400 mg BID, 500 mg BID, and up to 3000 mg/day in one trial); durations ranged from 1 month to 6 months.
- Key limitation
- High heterogeneity across trials (I2 up to 95% for several outcomes); small sample sizes in many RCTs; wide variation in resveratrol dose, formulation, and duration; several studies with unclear randomization or blinding; incomplete outcome data in some trials; safety data limited.
View source
Open PDFOriginal abstract
Background Diabetes is a major public health concern. Resveratrol has shown great beneficial effects on hyperglycemia and insulin resistance and as an antioxidant. Methods We searched the Chinese and English databases (such as CNKI, PubMed, and Embase) and extracted data from randomized controlled trials (RCTs). Then, RevMan 5.3 was used for bias risk assessment and meta-analysis. The primary outcome indicators include insulin-resistance-related indicators and blood-lipid-related indicators. This systematic review and meta-analysis was registered in PROSPERO (CRD42018089521). Results Fifteen RCTs involving 896 patients were included. For insulin-resistance-related indicators, the summary results showed that, compared with the control group, homeostasis model assessment for insulin resistance (HOMA-IR) in the resveratrol group is lower (WMD: −0.99; 95% CI −1.61, −0.38; P=0.002). For blood-lipid-related indicators, the total cholesterol (TC) and triglyceride (TG) in the resveratrol group is of no statistical significance (for TC, WMD: −7.11; 95% CI −16.28, 2.06; P=0.13; for TG, WMD: −2.15; 95% CI −5.52, 1.22; P=0.21). For adverse events, the summary results showed that there was no statistical difference in the incidence of adverse events between the resveratrol and control groups (WMD: 2; 95% CI 0.44, 9.03; P=0.37). Conclusion Based on the current evidence, resveratrol may improve insulin resistance, lower fasting blood glucose and insulin levels, and improve oxidative stress in patients with type 2 diabetes mellitus.